Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

被引：40
作者：
Thakurta, A. [1 ]
Gandhi, A. K. [1 ]
Waldman, M. F. [1 ]
Bjorklund, C. [1 ]
Ning, Y. [1 ]
Mendy, D. [1 ]
Schafer, P. [1 ]
Lopez-Girona, A. [1 ]
Lentzsch, S. [2 ]
Schey, S. A. [3 ,4 ]
Calle, Y. [3 ,4 ]
Chelliah, R. [3 ,4 ]
Orlowski, R. Z. [5 ]
Madan, A. [6 ]
Avet-Loiseau, H. [7 ]
Chopra, R. [1 ]
机构：
[1] Celgene Corp, Translat Dev, Summit, NJ 07901 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[3] Kings Coll Hosp London, Dept Haematooncol, London, England
[4] Kings Coll London, London, England
[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[6] Covance Genom Lab, Seattle, WA USA
[7] Univ Hosp, Unite Genom Myelome, Toulouse, France
来源：
LEUKEMIA | 2014年 / 28卷 / 05期
关键词：
LENALIDOMIDE; EXPRESSION; TARGET;
D O I：
10.1038/leu.2013.315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1129 / 1131
页数：3
相关论文
共 13 条
  • [1] High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Broyl, Annemiek
    Kuiper, Rowan
    van Duin, Mark
    van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Zweegman, Sonja
    Buijs, Arjan
    Hose, Dirk
    Lokhorst, Henk M.
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    [J]. BLOOD, 2013, 121 (04) : 624 - 627
  • [2] Initial genome sequencing and analysis of multiple myeloma
    Chapman, Michael A.
    Lawrence, Michael S.
    Keats, Jonathan J.
    Cibulskis, Kristian
    Sougnez, Carrie
    Schinzel, Anna C.
    Harview, Christina L.
    Brunet, Jean-Philippe
    Ahmann, Gregory J.
    Adli, Mazhar
    Anderson, Kenneth C.
    Ardlie, Kristin G.
    Auclair, Daniel
    Baker, Angela
    Bergsagel, P. Leif
    Bernstein, Bradley E.
    Drier, Yotam
    Fonseca, Rafael
    Gabriel, Stacey B.
    Hofmeister, Craig C.
    Jagannath, Sundar
    Jakubowiak, Andrzej J.
    Krishnan, Amrita
    Levy, Joan
    Liefeld, Ted
    Lonial, Sagar
    Mahan, Scott
    Mfuko, Bunmi
    Monti, Stefano
    Perkins, Louise M.
    Onofrio, Robb
    Pugh, Trevor J.
    Rajkumar, S. Vincent
    Ramos, Alex H.
    Siegel, David S.
    Sivachenko, Andrey
    Stewart, A. Keith
    Trudel, Suzanne
    Vij, Ravi
    Voet, Douglas
    Winckler, Wendy
    Zimmerman, Todd
    Carpten, John
    Trent, Jeff
    Hahn, William C.
    Garraway, Levi A.
    Meyerson, Matthew
    Lander, Eric S.
    Getz, Gad
    Golub, Todd R.
    [J]. NATURE, 2011, 471 (7339) : 467 - 472
  • [3] Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease
    Egan, Jan B.
    Kortuem, K. Martin
    Kurdoglu, Ahmet
    Izatt, Tyler
    Aldrich, Jessica
    Reiman, Rebecca
    Phillips, Lori
    Baker, Angela
    Shi, Chang-Xin
    Schmidt, Jessica
    Liang, Winnie S.
    Craig, David W.
    Carpten, John D.
    Stewart, A. Keith
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) : 748 - 751
  • [4] Gandhi AK., 2012, Blood, V120
  • [5] Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
    Gandhi, Anita K.
    Mendy, Derek
    Waldman, Michelle
    Chen, Gengxin
    Rychak, Emily
    Miller, Karen
    Gaidarova, Svetlana
    Ren, Yan
    Wang, Maria
    Breider, Michael
    Carmel, Gilles
    Mahmoudi, Afshin
    Jackson, Pilgrim
    Abbasian, Mahan
    Cathers, Brian E.
    Schafer, Peter H.
    Daniel, Tom O.
    Lopez-Girona, Antonia
    Thakurta, Anjan
    Chopra, Rajesh
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (02) : 233 - 244
  • [6] High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
    Heintel, Daniel
    Rocci, Alberto
    Ludwig, Heinz
    Bolomsky, Arnold
    Caltagirone, Simona
    Schreder, Martin
    Pfeifer, Sabine
    Gisslinger, Heinz
    Zojer, Niklas
    Jaeger, Ulrich
    Palumbo, Antonio
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) : 695 - 700
  • [7] A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation
    Higgins, JJ
    Pucilowska, J
    Lombardi, RQ
    Rooney, JP
    [J]. NEUROLOGY, 2004, 63 (10) : 1927 - 1931
  • [8] Identification of a Primary Target of Thalidomide Teratogenicity
    Ito, Takumi
    Ando, Hideki
    Suzuki, Takayuki
    Ogura, Toshihiko
    Hotta, Kentaro
    Imamura, Yoshimasa
    Yamaguchi, Yuki
    Handa, Hiroshi
    [J]. SCIENCE, 2010, 327 (5971) : 1345 - 1350
  • [9] Cereblon expression in multiple myeloma: not ready for prime time
    Lode, Laurence
    Amiot, Martine
    Maiga, Sophie
    Touzeau, Cyrille
    Menard, Audrey
    Magrangeas, Florence
    Minvielle, Stephane
    Pellat-Deceunynck, Catherine
    Bene, Marie-Christine
    Moreau, Philippe
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (02) : 282 - 284
  • [10] Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
    Lopez-Girona, A.
    Mendy, D.
    Ito, T.
    Miller, K.
    Gandhi, A. K.
    Kang, J.
    Karasawa, S.
    Carmel, G.
    Jackson, P.
    Abbasian, M.
    Mahmoudi, A.
    Cathers, B.
    Rychak, E.
    Gaidarova, S.
    Chen, R.
    Schafer, P. H.
    Handa, H.
    Daniel, T. O.
    Evans, J. F.
    Chopra, R.
    [J]. LEUKEMIA, 2012, 26 (11) : 2326 - 2335
12